Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Nov;119(6):1255–1261. doi: 10.1111/j.1476-5381.1996.tb16030.x

The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

K H Banner 1, E Moriggi 1, B Da Ros 1, G Schioppacassi 1, C Semeraro 1, C P Page 1
PMCID: PMC1915886  PMID: 8937731

Abstract

1. This study aimed to evaluate the effects of phosphodiesterase (PDE) inhibitors and currently prescribed anti-asthma drugs for their ability to inhibit inflammatory cell activation in vitro. 2. Alveolar macrophages and eosinophils were isolated from the bronchoalveolar lavage (BAL) fluid of ovalbumin (Ovalb)-sensitized guinea-pigs. Opsonized zymosan (OZ) and PAF stimulated leukotriene B4 (LTB4) release from eosinophils was measured by radioimmunoassay. Ovalb-induced superoxide generation was measured by reduction of cytochrome C. 3. Monocytes were separated from human peripheral venous blood and mast cells were dispersed from human lung fragments. Lipopolysaccharide (LPS)-induced tumour necrosis factor-alpha (TNF-alpha) release from monocytes was measured by ELISA and anti-IgE stimulated histamine release from mast cells was measured by a radioenzymatic method. 4. The beta 2 agonist, salbutamol inhibited TNF-alpha release from monocytes and histamine release from mast cells whilst having no effect on eosinophil-derived LTB4 release or macrophage superoxide generation. 5. The PDE 3 inhibitor, milrinone produced a concentration-related inhibition of TNF-alpha release from monocytes which achieved statistical significance at 10(-5) M but inhibited LTB4 release from eosinophils and superoxide generation from macrophages only at the highest concentration (10(-3) M) examined. Milrinone had no effect on histamine release from mast cells. 6. The selective PDE 4 inhibitors, denbufylline and rolipram and the corticosteroid, beclomethasone produced a concentration-related inhibition of LTB4 release from eosinophils, TNF-alpha release from monocytes and superoxide generation from alveolar macrophages whilst having no effect on histamine release from mast cells. 7. The mixed PDE 3/4 inhibitor, benzafentrine produced a concentration-related inhibition of LTB4 release from eosinophils, TNF-alpha release from monocytes, superoxide generation from alveolar macrophages and histamine release from mast cells. 8. In conclusion these data clearly show that both established anti-asthma medication as well as PDE inhibitors have the potential to inhibit inflammatory cell activation in vitro but that the anti-secretory actions of beta 2 agonists, corticosteroids and PDE inhibitors are distinct.

Full text

PDF
1261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azzawi M., Bradley B., Jeffery P. K., Frew A. J., Wardlaw A. J., Knowles G., Assoufi B., Collins J. V., Durham S., Kay A. B. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1407–1413. doi: 10.1164/ajrccm/142.6_Pt_1.1407. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J., Chung K. F., Page C. P. Inflammatory mediators and asthma. Pharmacol Rev. 1988 Mar;40(1):49–84. [PubMed] [Google Scholar]
  3. Barnette M. S., Manning C. D., Cieslinski L. B., Burman M., Christensen S. B., Torphy T. J. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther. 1995 May;273(2):674–679. [PubMed] [Google Scholar]
  4. Bauer A. C., Schwabe U. An improved assay of cyclic 3',5'-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn Schmiedebergs Arch Pharmacol. 1980 Mar;311(2):193–198. doi: 10.1007/BF00510259. [DOI] [PubMed] [Google Scholar]
  5. Brunelleschi S., Parenti A., Ceni E., Giotti A., Fantozzi R. Enhanced responsiveness of ovalbumin-sensitized guinea-pig alveolar macrophages to tachykinins. Br J Pharmacol. 1992 Dec;107(4):964–969. doi: 10.1111/j.1476-5381.1992.tb13392.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Butchers P. R., Skidmore I. F., Vardey C. J., Wheeldon A. Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro. Br J Pharmacol. 1980;71(2):663–667. doi: 10.1111/j.1476-5381.1980.tb10987.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  8. Calhoun W. J., Stevens C. A., Lambert S. B. Modulation of superoxide production of alveolar macrophages and peripheral blood mononuclear cells by beta-agonists and theophylline. J Lab Clin Med. 1991 Jun;117(6):514–522. [PubMed] [Google Scholar]
  9. Church M. K., Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol. 1987 Feb;90(2):421–429. doi: 10.1111/j.1476-5381.1987.tb08972.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dent G., Giembycz M. A., Rabe K. F., Barnes P. J. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br J Pharmacol. 1991 Jun;103(2):1339–1346. doi: 10.1111/j.1476-5381.1991.tb09790.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Durham S. R., Kay A. B. Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy. 1985 Sep;15(5):411–418. doi: 10.1111/j.1365-2222.1985.tb02290.x. [DOI] [PubMed] [Google Scholar]
  12. Elliott K. R., Leonard E. J. Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP. FEBS Lett. 1989 Aug 28;254(1-2):94–98. doi: 10.1016/0014-5793(89)81016-6. [DOI] [PubMed] [Google Scholar]
  13. Fuller R. W., O'Malley G., Baker A. J., MacDermot J. Human alveolar macrophage activation: inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition. Pulm Pharmacol. 1988;1(2):101–106. doi: 10.1016/s0952-0600(88)80006-1. [DOI] [PubMed] [Google Scholar]
  14. Hatzelmann A., Tenor H., Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol. 1995 Feb;114(4):821–831. doi: 10.1111/j.1476-5381.1995.tb13278.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Huang J. C., Garcia M. L., Reuben J. P., Kacsorowski G. J. Inhibition of beta-adrenoceptor agonist relaxation of airway smooth muscle by Ca(2+)-activated K+ channel blockers. Eur J Pharmacol. 1993 Apr 22;235(1):37–43. doi: 10.1016/0014-2999(93)90817-2. [DOI] [PubMed] [Google Scholar]
  16. Liggett S. B. Identification and characterization of a homogeneous population of beta 2-adrenergic receptors on human alveolar macrophages. Am Rev Respir Dis. 1989 Feb;139(2):552–555. doi: 10.1164/ajrccm/139.2.552. [DOI] [PubMed] [Google Scholar]
  17. Linden M. The effects of beta 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes. Br J Pharmacol. 1992 Sep;107(1):156–160. doi: 10.1111/j.1476-5381.1992.tb14479.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Miura M., Belvisi M. G., Stretton C. D., Yacoub M. H., Barnes P. J. Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis. 1992 Jul;146(1):132–136. doi: 10.1164/ajrccm/146.1.132. [DOI] [PubMed] [Google Scholar]
  19. Molnar-Kimber K., Yonno L., Heaslip R., Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions. 1993;39(Spec No):C77–C79. doi: 10.1007/BF01972726. [DOI] [PubMed] [Google Scholar]
  20. Nielson C. P., Vestal R. E., Sturm R. J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol. 1990 Nov;86(5):801–808. doi: 10.1016/s0091-6749(05)80186-1. [DOI] [PubMed] [Google Scholar]
  21. Peters S. P., Schulman E. S., Schleimer R. P., MacGlashan D. W., Jr, Newball H. H., Lichtenstein L. M. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. Am Rev Respir Dis. 1982 Dec;126(6):1034–1039. doi: 10.1164/arrd.1982.126.6.1034. [DOI] [PubMed] [Google Scholar]
  22. Schade F. U., Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol. 1993 Jan 5;230(1):9–14. doi: 10.1016/0014-2999(93)90403-5. [DOI] [PubMed] [Google Scholar]
  23. Simpson A. W., Reeves M. L., Rink T. J. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol. 1988 Jun 15;37(12):2315–2320. doi: 10.1016/0006-2952(88)90357-7. [DOI] [PubMed] [Google Scholar]
  24. Souness J. E., Carter C. M., Diocee B. K., Hassall G. A., Wood L. J., Turner N. C. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem Pharmacol. 1991 Jul 25;42(4):937–945. doi: 10.1016/0006-2952(91)90056-b. [DOI] [PubMed] [Google Scholar]
  25. Souness J. E., Maslen C., Webber S., Foster M., Raeburn D., Palfreyman M. N., Ashton M. J., Karlsson J. A. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br J Pharmacol. 1995 May;115(1):39–46. doi: 10.1111/j.1476-5381.1995.tb16317.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tenor H., Hatzelmann A., Kupferschmidt R., Stanciu L., Djukanović R., Schudt C., Wendel A., Church M. K., Shute J. K. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy. 1995 Jul;25(7):625–633. doi: 10.1111/j.1365-2222.1995.tb01110.x. [DOI] [PubMed] [Google Scholar]
  27. Torphy T. J., Undem B. J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 1991 Jul;46(7):512–523. doi: 10.1136/thx.46.7.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Verghese M. W., McConnell R. T., Lenhard J. M., Hamacher L., Jin S. L. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol. 1995 Jun;47(6):1164–1171. [PubMed] [Google Scholar]
  29. Yukawa T., Ukena D., Kroegel C., Chanez P., Dent G., Chung K. F., Barnes P. J. Beta 2-adrenergic receptors on eosinophils. Binding and functional studies. Am Rev Respir Dis. 1990 Jun;141(6):1446–1452. doi: 10.1164/ajrccm/141.6.1446. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES